A study of the probit model with latent variables in Phase I clinical trials (Q5220814): Difference between revisions

From MaRDI portal
Set OpenAlex properties.
ReferenceBot (talk | contribs)
Changed an Item
 
Property / cites work
 
Property / cites work: Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer / rank
 
Normal rank
Property / cites work
 
Property / cites work: Operating characteristics of the standard phase I clinical trial design. / rank
 
Normal rank
Property / cites work
 
Property / cites work: Consistency of continual reassessment method under model misspecification / rank
 
Normal rank
Property / cites work
 
Property / cites work: Dose Finding for Continuous and Ordinal Outcomes with a Monotone Objective Function: A Unified Approach / rank
 
Normal rank
Property / cites work
 
Property / cites work: Two-dimensional toxic dose and multivariate logistic regression, with application to decompression sickness / rank
 
Normal rank
Property / cites work
 
Property / cites work: On the multivariate predictive distribution of multi-dimensional effective dose: a Bayesian approach / rank
 
Normal rank
Property / cites work
 
Property / cites work: Bayesian analysis of dichotomous quantal response models / rank
 
Normal rank
Property / cites work
 
Property / cites work: Bayesian Analysis of Binary and Polychotomous Response Data / rank
 
Normal rank
Property / cites work
 
Property / cites work: Sampling-Based Approaches to Calculating Marginal Densities / rank
 
Normal rank
Property / cites work
 
Property / cites work: A phase I dose-finding study based on polychotomous toxicity responses / rank
 
Normal rank

Latest revision as of 03:47, 22 July 2024

scientific article; zbMATH DE number 7183154
Language Label Description Also known as
English
A study of the probit model with latent variables in Phase I clinical trials
scientific article; zbMATH DE number 7183154

    Statements

    A study of the probit model with latent variables in Phase I clinical trials (English)
    0 references
    0 references
    0 references
    0 references
    27 March 2020
    0 references
    Bayesian method
    0 references
    continual reassessment method
    0 references
    dose finding
    0 references
    latent variable
    0 references
    Markov chain Monte Carlo
    0 references
    phase I clinical trial
    0 references
    probit model
    0 references

    Identifiers